Published in Cancer Weekly, March 23rd, 1998
Both in vitro and in vivo data have demonstrated the unique targeting abilities of monoclonal antibodies (MoAbs). Although research with MoAbs has been encouraging, clinical applications have been limited.
Holger N. Lode and colleagues from The Scripps Research Institute, California, suggested that a strategy to increase the therapeutic efficiency of MoAbs would be to additionally stimulate effector cells by means of immunomodulators such as IL-2 ("Natural Killer Cell-Mediated Eradication of Neuroblastoma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.